Advertisement
According to the decision, DVC will continue development of a recombinantplague vaccine candidate, rF1V, up to and including possible licensure by theU.S. Food and Drug Administration (FDA). The vaccine candidate is currentlyin Phase 2 clinical trials.
Advertisement
"We are pleased with the DoD's decision to move forward with developmentof rF1V," said Dr. Robert V. House, president of DVC. "This will allow us tofocus our full energies on developing this crucial vaccine for protecting ournation's warfighters."
"We are very pleased that a decision has been made regarding a futureplague vaccine for the DoD," said Richard Nidel, Deputy Joint Product Managerfor the Joint Vaccine Acquisition Program.
Work will be performed by DVC at its headquarters in Frederick, Md., andat various subcontractor sites.
The rF1V plague vaccine candidate is designed to provide protectionagainst the plague bacterium Yersinia pestis in aerosolized form. The vaccinewas originally identified and developed by scientists working at the U.S. ArmyMedical Research Institute of Infectious Diseases (USAMRIID). Their workinvolved the identification of suitable protein antigens and the developmentof the processes used to assess the performance of the vaccine. Furtherdevelopment and manufacture of the vaccine candidate has been achieved by DVCunder the DoD JVAP contract. DVC has served as prime systems contractor forthe JVAP since 1997.
The safety and efficacy of this product in humans has not beenestablished. The product is currently under clinical investigation and hasnot been licensed by the FDA.
About JVAP
As part of the JPEO-CBD, JVAP's mission is to develop, produce, andstockpile FDA-licensed vaccine products to help protect the warfighter againstbiological warfare agents. JVAP consolidates the Department of Defense'sefforts for the advanced development, testing, FDA licensing, production andstorage of biological defense vaccines and other biologics.
About USAMRIID
The United States Army Medical Research Institute for Infectious Diseases(USAMRIID), located at Fort Detrick, Md., is the lead medical researchlaboratory for the U.S. Biological Defense Research Program, and plays a keyrole in national defense and in infectious diseases research. The Institute'smission is to conduct basic and applied research on biological threatsresulting in medical solutions (such as vaccines, drugs and diagnostics) toprotect the warfighter. USAMRIID is a subordinate laboratory of the U.S. ArmyMedical Research and Materiel Command.
About DVC
DynPort Vaccine Company LLC (DVC) manages product development programs andprovides consulting, technical and program management services to U.S.government agencies and companies in the biotechnology and pharmaceuticalindustries. For more information, visit http://www.csc.com/dvc. DVC is part ofCSC's North American Public Sector business unit's Government Health ServicesDivision. CSC's expertise in providing health services to government agencieshas grown over the last five decades to offer commercial best practicesintegrated to meet federal, state and local healthcare requirements. Servicesrange from optimizing claims processing to operating disease surveillancesystems to vaccine development and management. CSC's ideas and solutions areimproving the quality of health care with better information for betterdecisions to save lives and money.
About CSC
